JP6953444B2 - Ｐｅｔイメージング用免疫修飾因子 - Google Patents

Ｐｅｔイメージング用免疫修飾因子 Download PDF

Info

Publication number
JP6953444B2
JP6953444B2 JP2018560588A JP2018560588A JP6953444B2 JP 6953444 B2 JP6953444 B2 JP 6953444B2 JP 2018560588 A JP2018560588 A JP 2018560588A JP 2018560588 A JP2018560588 A JP 2018560588A JP 6953444 B2 JP6953444 B2 JP 6953444B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
ethoxy
tissue
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520328A (ja
JP2019520328A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド・ジェイ・ドネリー
ケネス・エム・ボーイ
ユンフイ・チャン
キム・ジュニョン
アドリエンヌ・ペナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019520328A publication Critical patent/JP2019520328A/ja
Publication of JP2019520328A5 publication Critical patent/JP2019520328A5/ja
Application granted granted Critical
Publication of JP6953444B2 publication Critical patent/JP6953444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018560588A 2016-05-19 2017-05-17 Ｐｅｔイメージング用免疫修飾因子 Active JP6953444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
US62/338,872 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (3)

Publication Number Publication Date
JP2019520328A JP2019520328A (ja) 2019-07-18
JP2019520328A5 JP2019520328A5 (cg-RX-API-DMAC7.html) 2020-06-25
JP6953444B2 true JP6953444B2 (ja) 2021-10-27

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560588A Active JP6953444B2 (ja) 2016-05-19 2017-05-17 Ｐｅｔイメージング用免疫修飾因子

Country Status (25)

Country Link
US (2) US11103605B2 (cg-RX-API-DMAC7.html)
EP (2) EP3827849A1 (cg-RX-API-DMAC7.html)
JP (1) JP6953444B2 (cg-RX-API-DMAC7.html)
KR (1) KR102378288B1 (cg-RX-API-DMAC7.html)
CN (1) CN109414514B (cg-RX-API-DMAC7.html)
AU (1) AU2017268291B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018073642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024844A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124241T1 (cg-RX-API-DMAC7.html)
DK (1) DK3458111T3 (cg-RX-API-DMAC7.html)
EA (1) EA038019B1 (cg-RX-API-DMAC7.html)
ES (1) ES2864091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210644T8 (cg-RX-API-DMAC7.html)
HU (1) HUE054306T2 (cg-RX-API-DMAC7.html)
IL (1) IL262962B (cg-RX-API-DMAC7.html)
LT (1) LT3458111T (cg-RX-API-DMAC7.html)
MA (1) MA53402A (cg-RX-API-DMAC7.html)
MX (1) MX2018014028A (cg-RX-API-DMAC7.html)
PL (1) PL3458111T3 (cg-RX-API-DMAC7.html)
PT (1) PT3458111T (cg-RX-API-DMAC7.html)
RS (1) RS61742B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810177VA (cg-RX-API-DMAC7.html)
SI (1) SI3458111T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100238T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017201111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
EP3558395A4 (en) 2016-12-23 2020-08-12 The Johns Hopkins University IMAGING OF TUMOR CELLS AND IMMUNE CELLS BASED ON PD-L1 EXPRESSION
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
EP4121442A1 (en) * 2020-03-16 2023-01-25 Bristol-Myers Squibb Company Immunomodulators
WO2021202501A1 (en) 2020-03-30 2021-10-07 Bristol-Myers Squibb Company Immunomodulators
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
EP4634205A2 (en) * 2022-12-12 2025-10-22 Merck Sharp & Dohme LLC Cyclic peptides as pet imaging agents of granzyme b

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
ATE380038T1 (de) 1996-07-12 2007-12-15 Immunomedics Inc Radiometall-bindende peptide analoge
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
CA2302360C (en) 1997-09-03 2005-11-15 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US10195578B2 (en) 2010-12-03 2019-02-05 The University Of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
MX2014011353A (es) 2012-03-29 2014-12-05 Aurigene Discovery Tech Ltd Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
MY176706A (en) 2013-03-15 2020-08-19 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
HUE039012T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EA037590B1 (ru) * 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
CA2968961A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
PT3458111T (pt) 2021-04-09
KR20190009330A (ko) 2019-01-28
EP3458111B1 (en) 2021-03-03
AU2017268291B2 (en) 2022-09-29
SG11201810177VA (en) 2018-12-28
IL262962A (en) 2018-12-31
EA201892635A1 (ru) 2019-04-30
WO2017201111A1 (en) 2017-11-23
AU2017268291A1 (en) 2019-01-17
RS61742B1 (sr) 2021-05-31
SI3458111T1 (sl) 2021-07-30
EP3458111A1 (en) 2019-03-27
EA038019B1 (ru) 2021-06-23
HRP20210644T1 (hr) 2021-05-28
MX2018014028A (es) 2019-04-04
CY1124241T1 (el) 2022-07-22
BR112018073642A2 (pt) 2019-02-26
SMT202100238T1 (it) 2021-05-07
CN109414514B (zh) 2022-03-11
CA3024844A1 (en) 2017-11-23
HUE054306T2 (hu) 2021-08-30
JP2019520328A (ja) 2019-07-18
HRP20210644T8 (hr) 2021-06-25
US20190117801A1 (en) 2019-04-25
MA53402A (fr) 2021-06-02
PL3458111T3 (pl) 2021-06-28
ES2864091T3 (es) 2021-10-13
DK3458111T3 (da) 2021-04-26
US11103605B2 (en) 2021-08-31
KR102378288B1 (ko) 2022-03-23
IL262962B (en) 2020-04-30
EP3827849A1 (en) 2021-06-02
LT3458111T (lt) 2021-05-25
US20210386876A1 (en) 2021-12-16
CN109414514A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
JP6953444B2 (ja) Ｐｅｔイメージング用免疫修飾因子
JP7027480B2 (ja) 生物学的製剤の１８ｆ－放射性標識方法および組成物
US20160303258A1 (en) Compounds and compositions for imaging gcc-expressing cells
Zhu et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
AU2023347470A1 (en) High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
Lamba et al. Synthetic 18 F labeled biomolecules that are selective and promising for PET imaging: major advances and applications
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
JP2008531988A (ja) 放射性標識ガリウム錯体、その合成法並びに悪性腫瘍におけるｅｇｆｒ発現のｐｅｔイメージングにおける使用
CN119113155A (zh) 放射性核素标记的靶向pd-l1小蛋白及其制备方法与应用
US20250135049A1 (en) Methods for Biological Material Labeling and Medical Imaging
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
Zeglis et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Ebenhan et al. Radiochemistry
Keeling et al. Nuclear Imaging of Inflammation
Liang et al. Preclinical evaluation of 89Zr/177Lu-labelled anti-B7-H3 monoclonal antibody for theranostics in B7-H3-positive liver cancer
Fougère et al. of poppy seed oil (lipiodol® ultra-fluid), a new TARE formulation, designed from a lipophilic ligand for stability and safety
Hu Xiaoyan Li
Pang et al. 68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging
CN119015451A (zh) 一种靶向pd-l1的核素蛋白探针及其应用
CN119661694A (zh) 一种靶向mt1-mmp的pet显像剂及其制备方法和应用
CN120247876A (zh) 靶向肿瘤相关成纤维细胞的分子探针及其制备方法和应用
Xiao Development and Evaluation of Molecular Imaging Agents for Inflammation and Cancer
CN110551075A (zh) 放射性标记亚谷氨基酸类化合物及其在制备pet显像剂的应用
Cassells et al. –Preclinical evaluation of a terbium-161 labelled half-life extended anti-c-Met Nanobody®(vHH)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210929

R150 Certificate of patent or registration of utility model

Ref document number: 6953444

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250